A deal between Medivation and BioMarin for cancer asset talazoparib exemplifies the sort of deals the industry saw from big pharma last year as BioMarin tries to focus on its area of strength – rare disease drugs.
The two biotechs announced Aug. 24 that BioMarin will divest its late-stage orally-available poly ADP ribose polymerase (PARP) inhibitor to...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

